C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/09 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2700498
The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations.
Dans la région variable, la région charpente et la région constante de TOCILIZUMAB, on a découvert une mutation spécifique d'acide aminé qui potentialise une capacité de liaison à l'antigène, augmente la cinétique des médicaments, abaisse un risque immunogénique, augmente la stabilité dans des conditions acides, améliore l'hétérogénéité grâce à un disulfure dans la région charnière, améliore la stabilité d'une préparation à concentrations élevées, etc.
Igawa Tomoyuki
Kojima Tetsuo
Maeda Atsuhiko
Sakurai Mika
Shiraiwa Hirotake
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Chugai Seiyaku Kabushiki Kaisha
LandOfFree
Anti-il-6 receptor antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-il-6 receptor antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-il-6 receptor antibody will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1869877